Biotech Values

[mbmalone]

XOMA's technologies enable them to co-formulate and deliver multiple antibodies in a single injectable solution. This facilitates delivery and has the potential to increase efficacy for infectious and other diseases. XOMA 3AB consists of three human antibodies that bind to unique epitopes on the botulinum A toxin, which in composite provide unprecedented potency against the toxin.

They designed XOMA 3AB to neutralize botulinum neurotoxin Type A, which causes paralysis and is a bioterror threat. The presentation of the results was at the 20th Annual International Conference on Antibody Engineering held December 6 to 10 in San Diego, California.

This stock is set to explode on Bioterror threat/hype. It's been irrationally oversold.